WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205820
Description: AZD7451, also known as AZ12607092, is a tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. AZD7451 binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.
MedKoo Cat#: 205820
Chemical Formula: C18H19FN8O
Exact Mass: 382.1666
Molecular Weight: 382.4034
Elemental Analysis: C, 56.54; H, 5.01; F, 4.97; N, 29.30; O, 4.18
AZD7451, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: AZD-7451; AZD7451; AZD 7451; AZ12607092; AZ 12607092; AZ-12607092.
IUPAC/Chemical Name: (S)-N-(1-(5-fluoropyrimidin-2-yl)ethyl)-3-(5-isopropoxy-1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-amine
InChi Key: AYOOGWWGECJQPI-NSHDSACASA-N
InChi Code: InChI=1S/C18H19FN8O/c1-10(2)28-16-6-15(25-26-16)27-9-22-13-4-5-14(24-18(13)27)23-11(3)17-20-7-12(19)8-21-17/h4-11H,1-3H3,(H,23,24)(H,25,26)/t11-/m0/s1
SMILES Code: C[C@H](NC1=CC=C2C(N(C3=NNC(OC(C)C)=C3)C=N2)=N1)C4=NC=C(F)C=N4
The following data is based on the product molecular weight 382.4034 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, Moriyama S, Yano M, Brown J, Fujii Y. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.. Mol Clin Oncol. 2014 Sep;2(5):725-730. Epub 2014 Jun 19. PubMed PMID: 25054037; PubMed Central PMCID: PMC4106662.
2: Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD. A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12. doi: 10.1016/j.jchromb.2013.10.023. Epub 2013 Oct 22. PubMed PMID: 24239935; PubMed Central PMCID: PMC3864870.
3: Ivanov SV, Panaccione A, Brown B, Guo Y, Moskaluk CA, Wick MJ, Brown JL, Ivanova AV, Issaeva N, El-Naggar AK, Yarbrough WG. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. Oncogene. 2013 Aug 8;32(32):3698-710. doi: 10.1038/onc.2012.377. Epub 2012 Oct 1. PubMed PMID: 23027130.